Condition (MeSH)
Telangiectasia, Hereditary Hemorrhagic
ClinicalTrials.gov lists 105 trials for Telangiectasia, Hereditary Hemorrhagic or a narrower condition beneath it. National Center for Research Resources (NCRR) has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
105 of the 105 trials are tagged with Telangiectasia, Hereditary Hemorrhagic itself; the rest are tagged with a narrower condition beneath it.
When did Telangiectasia, Hereditary Hemorrhagic trials start? (27)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 5 |
| 2024 | 5 |
| 2023 | 6 |
| 2022 | 5 |
| 2021 | 3 |
| 2020 | 7 |
| 2019 | 5 |
| 2018 | 7 |
| 2017 | 4 |
Showing 10 of 27 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 7 trials starting in 2026 and about 6 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 35 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 36 months across 66 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Telangiectasia, Hereditary Hemorrhagic trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 7 |
| Phase 1/2 | 8 |
| Phase 2 | 22 |
| Phase 2/3 | 2 |
| Phase 3 | 7 |
| Phase 4 | 2 |
| Not applicable | 15 |
| Observational | 42 |
How many Telangiectasia, Hereditary Hemorrhagic trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 15 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 8 |
| Completed | 62 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Telangiectasia, Hereditary Hemorrhagic trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Center for Research Resources (NCRR) | 4 |
| Vaderis Therapeutics AG | 2 |
| Alnylam Pharmaceuticals | 1 |
| Atavistik Bio, Inc | 1 |
Which drugs are being tested for Telangiectasia, Hereditary Hemorrhagic? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| THALIDOMIDE | 2 |
| POMALIDOMIDE | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Bevacizumab 1 | 11 |
| Pazopanib Pill | 3 |
| NaCl 0.9% NS | 2 |
| acid tranexamic | 2 |
| Calcium/Vit D | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Telangiectasia, Hereditary Hemorrhagic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 4 | 1 |
| Epistaxis | 3 | 2 |
| Gastrointestinal haemorrhage | 3 | 1 |
| Anaemia | 2 | 1 |
| Cardiac failure congestive | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Telangiectasia, Hereditary Hemorrhagic? (108)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Treatment of epistaxis in Osler-Weber-Rendu disease by bevacizumab nasal spray. The EROSB study: Determining the effective dose. | European annals of otorhinolaryngology, head and neck diseases | 2025 | Yes |
| Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia. | The New England journal of medicine | 2025 | Yes |
| Updates on diagnostic criteria for hereditary haemorrhagic telangiectasia in the light of whole genome sequencing of 'gene-negative' individuals recruited to the 100 000 Genomes Project. | Journal of medical genetics | 2024 | Yes |
| Iron deficiency responses and integrated compensations in patients according to hereditary hemorrhagic telangiectasia <i>ACVRL1, ENG</i> and <i>SMAD4</i> genotypes. | Haematologica | 2024 | Yes |
| Assessing the Psychometric Validity of the Epistaxis Severity Score: Internal Consistency and Test-Retest Reliability. | American journal of rhinology & allergy | 2024 | Yes |
Showing 5 of 108 publications.
Prevalence (21)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Hereditary hemorrhagic telangiectasia | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Hereditary hemorrhagic telangiectasia | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Hereditary hemorrhagic telangiectasia | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Unspecified |
| Hereditary hemorrhagic telangiectasia | Point prevalence | 1-9 / 100 000 | United States | US | Exact |
| Hereditary hemorrhagic telangiectasia | Point prevalence | 1-9 / 100 000 | United States | US | Unspecified |
Showing 5 of 21 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Hereditary hemorrhagic telangiectasia | 774 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Hereditary hemorrhagic telangiectasia | 774 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.